Spots Global Cancer Trial Database for Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
Official Title: A Randomized Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of Topical Bimiralisib Application in Participants Suffering From Actinic Keratosis on the Face and/or Scalp and/or Back of Hands Over a 2 and 4-week Treatment Period
Study ID: NCT06319794
Conditions
Study Description
Brief Summary: The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
Detailed Description: This is a multi-center, randomized, open label, parallel group study. The study products will be applied to the target lesions for a duration of 2 or 4 weeks of treatment. The study consists of the following periods: * Screening (up to 30 days) * Treatment (2 or 4 weeks) * Follow-Up (4 weeks) Participants will be randomized to one of two groups (1:1): * Arm A: Topical bimiralisib gel treatment for 2 weeks * Arm B: Topical bimiralisib gel treatment for 4 weeks
Keywords
Eligibility
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Basel / Department of Dermatology, Basel, , Switzerland
CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology, Lausanne, , Switzerland
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
